Literature DB >> 22453987

Remodeling of calcium handling in human heart failure.

Qing Lou1, Ajit Janardhan, Igor R Efimov.   

Abstract

Heart failure (HF) is an increasing public health problem accelerated by a rapidly aging global population. Despite considerable progress in managing the disease, the development of new therapies for effective treatment of HF remains a challenge. To identify targets for early diagnosis and therapeutic intervention, it is essential to understand the molecular and cellular basis of calcium handling and the signaling pathways governing the functional remodeling associated with HF in humans. Calcium (Ca(2+)) cycling is an essential mediator of cardiac contractile function, and remodeling of calcium handling is thought to be one of the major factors contributing to the mechanical and electrical dysfunction observed in HF. Active research in this field aims to bridge the gap between basic research and effective clinical treatments of HF. This chapter reviews the most relevant studies of calcium remodeling in failing human hearts and discusses their connections to current and emerging clinical therapies for HF patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22453987      PMCID: PMC3740791          DOI: 10.1007/978-94-007-2888-2_52

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  184 in total

1.  PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts.

Authors:  S O Marx; S Reiken; Y Hisamatsu; T Jayaraman; D Burkhoff; N Rosemblit; A R Marks
Journal:  Cell       Date:  2000-05-12       Impact factor: 41.582

2.  Diminished basal phosphorylation level of phospholamban in the postinfarction remodeled rat ventricle: role of beta-adrenergic pathway, G(i) protein, phosphodiesterase, and phosphatases.

Authors:  B Huang; S Wang; D Qin; M Boutjdir; N El-Sherif
Journal:  Circ Res       Date:  1999-10-29       Impact factor: 17.367

3.  Targeting phospholamban by gene transfer in human heart failure.

Authors:  Federica del Monte; Sian E Harding; G William Dec; Judith K Gwathmey; Roger J Hajjar
Journal:  Circulation       Date:  2002-02-26       Impact factor: 29.690

4.  Protein kinase A phosphorylation of the ryanodine receptor does not affect calcium sparks in mouse ventricular myocytes.

Authors:  Yanxia Li; Evangelia G Kranias; Gregory A Mignery; Donald M Bers
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

5.  Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.

Authors:  J N Cohn; S Ziesche; R Smith; I Anand; W B Dunkman; H Loeb; G Cintron; W Boden; L Baruch; P Rochin; L Loss
Journal:  Circulation       Date:  1997-08-05       Impact factor: 29.690

6.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.

Authors:  M Packer; C M O'Connor; J K Ghali; M L Pressler; P E Carson; R N Belkin; A B Miller; G W Neuberg; D Frid; J H Wertheimer; A B Cropp; D L DeMets
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

7.  Characteristics of calcium-current in isolated human ventricular myocytes from patients with terminal heart failure.

Authors:  D J Beuckelmann; M Näbauer; E Erdmann
Journal:  J Mol Cell Cardiol       Date:  1991-08       Impact factor: 5.000

8.  Intracellular calcium transient of working human myocardium of seven patients transplanted for congestive heart failure.

Authors:  C F Vahl; A Bonz; T Timek; S Hagl
Journal:  Circ Res       Date:  1994-05       Impact factor: 17.367

9.  Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats.

Authors:  Yoshitaka Iwanaga; Masahiko Hoshijima; Yusu Gu; Mitsuo Iwatate; Thomas Dieterle; Yasuhiro Ikeda; Moto-o Date; Jacqueline Chrast; Masunori Matsuzaki; Kirk L Peterson; Kenneth R Chien; John Ross
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

Review 10.  Sudden cardiac death in heart failure. The role of abnormal repolarization.

Authors:  G F Tomaselli; D J Beuckelmann; H G Calkins; R D Berger; P D Kessler; J H Lawrence; D Kass; A M Feldman; E Marban
Journal:  Circulation       Date:  1994-11       Impact factor: 29.690

View more
  46 in total

Review 1.  Obesity, Hypertension, and Cardiac Dysfunction: Novel Roles of Immunometabolism in Macrophage Activation and Inflammation.

Authors:  Alan J Mouton; Xuan Li; Michael E Hall; John E Hall
Journal:  Circ Res       Date:  2020-03-12       Impact factor: 17.367

Review 2.  'Ryanopathy': causes and manifestations of RyR2 dysfunction in heart failure.

Authors:  Andriy E Belevych; Przemysław B Radwański; Cynthia A Carnes; Sandor Györke
Journal:  Cardiovasc Res       Date:  2013-02-12       Impact factor: 10.787

Review 3.  Sarcoplasmic reticulum calcium mishandling: central tenet in heart failure?

Authors:  Amanda L Denniss; Alexander M Dashwood; Peter Molenaar; Nicole A Beard
Journal:  Biophys Rev       Date:  2020-07-22

Review 4.  Arrhythmogenic and metabolic remodelling of failing human heart.

Authors:  C R Gloschat; A C Koppel; K K Aras; J A Brennan; K M Holzem; I R Efimov
Journal:  J Physiol       Date:  2016-06-12       Impact factor: 5.182

5.  Heart failure prevention with sodium-glucose cotransporter 2 inhibitors.

Authors:  Muhammad Shahzeb Khan; Javed Butler
Journal:  J Diabetes       Date:  2019-05-01       Impact factor: 4.006

Review 6.  Myofilament dysfunction as an emerging mechanism of volume overload heart failure.

Authors:  Kristin Wilson; Pamela A Lucchesi
Journal:  Pflugers Arch       Date:  2014-02-01       Impact factor: 3.657

7.  Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity.

Authors:  Dylan J Richards; Yang Li; Charles M Kerr; Jenny Yao; Gyda C Beeson; Robert C Coyle; Xun Chen; Jia Jia; Brooke Damon; Robert Wilson; E Starr Hazard; Gary Hardiman; Donald R Menick; Craig C Beeson; Hai Yao; Tong Ye; Ying Mei
Journal:  Nat Biomed Eng       Date:  2020-04-13       Impact factor: 25.671

8.  Ranolazine prevents pressure overload-induced cardiac hypertrophy and heart failure by restoring aberrant Na+ and Ca2+ handling.

Authors:  Jiali Nie; Quanlu Duan; Mengying He; Xianqing Li; Bei Wang; Chi Zhou; Lujin Wu; Zheng Wen; Chen Chen; Dao Wu Wang; Katherina M Alsina; Xander H T Wehrens; Dao Wen Wang; Li Ni
Journal:  J Cell Physiol       Date:  2018-11-29       Impact factor: 6.384

Review 9.  Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure.

Authors:  Abhishek Jaiswal; Vinh Q Nguyen; Thierry H Le Jemtel; Keith C Ferdinand
Journal:  World J Cardiol       Date:  2016-07-26

Review 10.  From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure.

Authors:  Bianca C Bernardo; Burns C Blaxall
Journal:  Heart Lung Circ       Date:  2016-01-19       Impact factor: 2.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.